Methods of treating cancer using compositions of antibodies and carrier proteins with antibody pretreatment

1. A method for treating a patient suffering from a cancer which expresses VEGF wherein said patient is treated with a sub-therapeutic amount of an anti-VEGF antibody and albumin-bound chemotherapeutic/anti-VEGF antibody nanoparticle complexes containing a therapeutically effective amount of the chemotherapeutic such that the administration of said sub-therapeutic amount of the anti-VEGF antibody enhances the efficacy of said nanoparticle complexes, wherein the sub-therapeutic amount of anti-VEGF antibody is administered from between about 30 minutes to about 48 hours prior to administration of the albumin-bound chemotherapeutic/anti-VEGF antibody nanoparticle complexes; wherein the chemotherapeutic is paclitaxel and the anti-VEGF antibody is bevacizumab or a biosimilar version thereof, wherein a therapeutic dosage of the anti-VEGF antibody is about 5 mg/kg to about 15 mg/kg; and wherein the sub-therapeutic amount of anti-VEGF antibody is selected from an amount consisting of about 1%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, and about 60% of the therapeutic dosage of anti-VEGF antibody.

2. The method of claim 1 , wherein the sub-therapeutic amount of anti-VEGF antibody is an amount which blocks circulating VEGF without blocking VEGF on a target of said nanoparticle complexes.

3. The method of claim 2 , wherein the target of said nanoparticle complexes is a solid cancer.

4. The method of claim 1 , wherein the sub-therapeutic amount of anti-VEGF antibody to be administered to the patient is determined by analyzing the level of circulating VEGF in the blood.

5. A method for enhancing the efficacy of albumin-bound chemotherapeutic/anti-VEGF antibody nanoparticle complexes by administering the albumin-bound chemotherapeutic/anti-VEGF antibody nanoparticle complexes about 24 hours after administrating a sub-therapeutic amount of anti-VEGF antibody to a patient in need thereof; wherein the chemotherapeutic is paclitaxel and the anti-VEGF antibody is bevacizumab or a biosimilar version thereof, wherein a therapeutic dosage of the anti-VEGF antibody is about 5 mg/kg to about 15 mg/kg; and wherein the sub-therapeutic amount of anti-VEGF antibody is selected from an amount consisting of about 1%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, and about 60% of the therapeutic dosage of anti-VEGF antibody.

6. The method of claim 5 , wherein the sub-therapeutic amount of anti-VEGF antibody is an amount which blocks circulating VEGF without blocking VEGF on a target of said nanoparticle complexes.

7. The method of claim 6 , wherein the target of said nanoparticle complexes is a solid cancer.

8. The method of claim 5 , wherein the sub-therapeutic dose of anti-VEGF antibody to be administered to the patient is determined by analyzing the level of circulating VEGF in the blood.

9. The method of claim 5 , wherein the sub-therapeutic dose of the anti-VEGF antibody is administered from between about 30 minutes to about 48 hours prior to administration of the albumin-bound chemotherapeutic/anti-VEGF antibody nanoparticle complexes.

10. A method for enhancing the therapeutic outcome in a patient suffering from a cancer expressing soluble VEGF which patient is being treated with nanoparticle complexes comprising albumin-bound chemotherapeutic and anti-VEGF antibodies wherein said antibodies of the nanoparticle complexes are integrated onto and/or into said nanoparticle complexes, which method comprises treating said patient with a sub-therapeutic amount of said anti-VEGF antibody prior to treatment with the nanoparticle complexes; wherein the chemotherapeutic is paclitaxel and the anti-VEGF antibody is bevacizumab or a biosimilar version thereof, wherein a therapeutic dosage of the anti-VEGF antibody is about 5 mg/kg to about 15 mg/kg; and wherein the sub-therapeutic amount of anti-VEGF antibody is selected from an amount consisting of about 1%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, and about 60% of the therapeutic dosage of anti-VEGF antibody.

11. A method for enhancing the therapeutic outcome in a patient suffering from a cancer overexpressing soluble VEGF which patient has been treated with a sub-therapeutic amount of anti-VEGF antibody, said method comprising treating said patients with an effective amount of nanoparticle complexes comprising albumin-bound paclitaxel and anti-VEGF antibodies wherein said antibodies of the nanoparticle complexes are integrated onto and/or into said nanoparticle complexes; wherein the anti-VEGF antibody is bevacizumab or a biosimilar version thereof, wherein a therapeutic dosage of the anti-VEGF antibody is about 5 mg/kg to about 15 mg/kg; and wherein the sub-therapeutic amount of anti-VEGF antibody is selected from an amount consisting of about 1%, about 5%, about 10% about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, and about 60% of the therapeutic dosage of anti-VEGF antibody.